These data simultaneously reinforce other studies that identified drug synergy via the combined use of HDAC and PARP inhibitors in various cancer types [77,78,79,80] and predict that this combination therapy may increase fork degradation and subsequent cell death in BRCA-deficient cancers [76]. Here, HDAC9 is linked to cancer.